Moran Choe

United States Food and Drug Administration — United States

Medicine · Health Sciences

12h-index929citations38works0.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(12), Hormonal Regulation and Hypertension(8), Renal cell carcinoma treatment(7), Acute Myeloid Leukemia Research(5), Myeloproliferative Neoplasms: Diagnosis and Treatment(5)

Publications38 total

Evaluation of amplification potential of species identification markers in a virtual PCR environment and efficient molecular identification of three black truffle species by multiplex PCR assay
Vegetos·2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia
Journal of Clinical Oncology·2025
Supplementary Table S2 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Supplementary Table S1 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Supplementary Figure S1 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Supplementary Figure S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Supplementary Table S6 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Supplementary Table S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Supplementary Figure S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Supplementary Table S5 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Data from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Supplementary Table S7 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Supplementary Table S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
Supplementary Figure S2 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025Open Access
FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
Clinical Cancer Research·2025Open Access
ICH S7B hERG and cardiac repolarization assays do not address mechanisms of QT prolongation for peptide and protein products
Journal of Pharmacological and Toxicological Methods·2025
DNA barcode and sequence related amplified polymorphism markers reveal phylogenetic relationship among Pinus species representing closed lineage divergence
Genetic Resources and Crop Evolution·2025· 1 cited
Supplementary Table S2 from FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an <i>Isocitrate Dehydrogenase 1</i> Mutation
2025Open Access
Data from FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an <i>Isocitrate Dehydrogenase 1</i> Mutation
2025Open Access
Supplementary Table S1 from FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an <i>Isocitrate Dehydrogenase 1</i> Mutation
2025Open Access
page 1 of 2Next →

Frequent Co-authors

Brenda J. Gehrke(18), Jonathon Vallejo(18), Richard Pazdur(18), Marc R. Theoret(18), R. Angelo de Claro(18), Jiang Liu(17), Robert Q. Le(13), Kamar Godder(13), Justin S. Collazo(13), Robyn Konicki(13), Monica Feng(13), Donna Przepiorka(13), Ankit Shah(13), Willie Wilson(13), Andrea Siegel(13), Yun Wu(13), Charles Yuan-Chia Kuo(13), Melissa Ray(13), Antonino Passaniti(6), Jingyan Wang(6)